CryoPort (NASDAQ:CYRX) Releases Earnings Results, Misses Expectations By $0.07 EPS

CryoPort (NASDAQ:CYRX) announced its quarterly earnings data on Thursday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year, and raised its 2026 continuing-operations revenue outlook to $197 million–$199 million. Management characterized the outlook as prudent, with fourth-quarter growth expected to continue but potential upside.
• Life Sciences Services revenue rose 18%, including 20% growth in commercial cell and gene therapy activity; the company supports 23 commercial therapies and reported a record pipeline of 788 clinical trials, including 99 in Phase III. Management sees the pipeline and rising therapy adoption as drivers of future commercial growth.
• The company posted a second consecutive quarter of positive adjusted EBITDA, at $1.1 million and $1.8 million better year over year. Management expects further operating leverage as new BioServices capabilities come online, while noting that long-term margin targets remain goals rather than current results.
• Life science products revenue increased 8%, supported by animal-health demand and the Fusion freezer line, although management described animal health as cyclical and said China was stable but not a significant growth market. Four expected 2026 therapy application filings have shifted to 2027, while two potential fourth-quarter approvals have FDA decision dates.

CryoPort Stock Performance

Shares of CryoPort stock traded up $3.05 during trading hours on Friday, reaching $19.10. 2,585,565 shares of the company were exchanged, compared to its average volume of 854,852. The stock’s fifty day moving average is $16.98 and its 200 day moving average is $13.46. CryoPort has a 1 year low of $7.61 and a 1 year high of $19.53. The firm has a market cap of $967.42 million, a PE ratio of -19.69 and a beta of 1.89.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Robert W. Baird set a $26.00 price objective on CryoPort in a research report on Tuesday, October 13th. Weiss Ratings raised CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Needham & Company LLC increased their target price on shares of CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler upgraded CryoPort to a “buy” rating in a research report on Tuesday, October 13th. Finally, Guggenheim boosted their target price on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and an average target price of $21.69.

Insider Buying and Selling at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total value of $429,408.00. Following the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

More CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.